Legal Proceedings
−Removed: On May 6, 2024, a class action complaint was filed in federal district court in the District of Maryland, Southern Division, naming as defendants, the Company and three of the Company’s current executive officers, captioned Mogan v.
−Removed: Altimmune, Inc.
−Removed: , et al., No.
+Added: On May 6, 2024, a class action complaint was filed in federal district court in the District of Maryland, Southern Division, naming as defendants us and three of our executive officers, captioned Mogan v.
+Added: Altimmune, Inc., et al., No.
24-cv-01315 (D.
−Removed: The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact to the investing public including the plaintiff and class members, who purchased or otherwise acquired the Company’s common stock between December 1, 2023 and April 26, 2024.
−Removed: The plaintiff and class members seek to have the action maintained as a class action under Rule 23 of the Federal Rules of Civil Procedure
−Removed: and for the defendants to pay damages, interest, and an award of costs, including attorneys’ fees.
−Removed: The Company intends to vigorously defend against the lawsuit.
+Added: Md.) (the “Class Action”).
+Added: The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact to the investing public including the plaintiff and class members, who purchased or otherwise acquired our common stock between December 1, 2023 and April 26, 2024.
+Added: The plaintiff and class members seek to have the action maintained as a class action under Rule 23 of the Federal Rules of Civil Procedure and for the defendants to pay damages, interest, and an award of costs, including attorneys’ fees.
+Added: On June 14, 2024, the Court entered an order stating that defendants were not required to answer, move to dismiss, or otherwise respond to the initial complaint filed on May 6, 2024, and that within 14 days of the Court’s entry of an order appointing a lead plaintiff the parties are to confer and submit a proposed schedule to the court for the filing of an amended complaint (if any) and the filing of a motion to dismiss or other response to the amended complaint.
+Added: A substantially similar complaint, captioned Campanile v.
+Added: Altimmune, Inc., et al.
+Added: 8:24-cv-01918 (D.
+Added: Md.), was also filed in the same court by another plaintiff on July 1, 2024 against the Company and three of its executive officers, based upon the same general set of allegations and class period.
+Added: On July 5, 2024, two movants moved to consolidate the two actions and to be appointed lead plaintiff.
+Added: On July 12, 2024, these movants filed a stipulation and proposed order to consolidate the related actions, and to be appointed co-lead plaintiffs.
+Added: We intend to vigorously defend against this class action litigation.
+Added: On June 4, 2024, a shareholder derivative complaint was filed in federal district court in the District of Delaware, purportedly on behalf of us, naming as defendants three of our executive officers and eight of our board members, captioned Stourbridge Investments LLC v.
+Added: 1:24-cv-669-GBW (D.
+Added: The complaint is based upon allegations that are similar to those alleged in the Class Action and alleges claims for contribution, breaches of fiduciary duty, unjust enrichment, and waste of corporate assets based on the defendants purportedly making or causing to be made false and misleading statements and omissions of material fact between December 1, 2023 and April 26, 2024.
+Added: The complaint seeks unspecified monetary relief, exemplary damages, restitution, contribution, and costs, as well as equitable relief.
+Added: A similar shareholder derivative complaint was filed in the same court by another plaintiff on July 1, 2024, based upon substantially similar allegations, and alleges claims for contribution, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets.
+Added: The complaint, captioned Alaraidah v.
+Added: 1:24-cv-00772-GBW (D.
+Added: Del.), seeks unspecified monetary relief, restitution, costs, and equitable relief.
+Added: These actions were consolidated on July 18, 2024 into case no.
+Added: 1:24-cv-669-GBW (the “Derivative Action”).
+Added: We intend to vigorously defend against the Derivative Action.
From time to time, we may be involved in various legal proceedings or investigations, which could be costly and impose a significant burden on management and employees.
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.